Live Database · Updated Weekly

Clinical GuidelinesIndexed for Doctors.

Every major guideline from ADA, AHA, BTS, EASD, ERS and 5 more societies — instantly searchable, AI-annotated, and always up to date.

ADAAHABTSEASDERSESCEULARIDSAKDIGONICE

20+Clinical Guidelines

10Medical Societies

8Specialties Covered

40+Countries Represented

7 new guidelines added recently·6 guidelines updated

Browse by Specialty

8 specialties

Cardiology9 guidelines

Endocrinology2 guidelines

Infectious Disease1 guideline

Nephrology2 guidelines

Neurology1 guideline

Psychiatry1 guideline

Respiratory Medicine3 guidelines

Rheumatology1 guideline

AI Search

20 of 20 guidelines

Specialty

Society

All Guidelines

Showing 20 of 20 clinical guidelines

CardiologyESCNew

Heart Failure 2023

The 2023 ESC Heart Failure Guidelines update the evidence base for four-pillar therapy (ARNI, beta-blocker, MRA, SGLT2-i) and extend recommendations to HFpEF with empagliflozin and dapagliflozin. Simultaneous low-dose initiation is now preferred over sequential up-titration.

Heart FailureHFrEFHFpEF+3

128p2023EU

CardiologyESC

Atrial Fibrillation 2020

Introduces the ABC pathway (Anticoagulation, Better symptom control, Cardiovascular risk reduction) for structured AF management. Oral anticoagulation with NOACs is strongly preferred over VKAs for stroke prevention. The CHA₂DS₂-VASc score guides anticoagulation decisions.

Atrial FibrillationNOACsStroke prevention+2

100p2020EU

CardiologyESCNew

Acute Coronary Syndromes 2023

Unified ACS guidelines replacing separate STEMI/NSTEMI documents. Includes updated revascularisation strategies, de-escalation of P2Y12 therapy, colchicine for secondary prevention, and expanded indications for ticagrelor monotherapy after 3-month DAPT.

ACSSTEMINSTEMI+3

112p2023EU

EndocrinologyADANew

Standards of Care 2024

Comprehensive annual update to diabetes standards. Highlights include expanded GLP-1 RA and SGLT2-i indications independent of HbA1c, tirzepatide approved for weight management, and revised HbA1c targets based on individualized patient goals. Technology integration (CGM, automated insulin delivery) is now standard of care.

Type 2 DiabetesGLP-1SGLT2i+3

256p2024USA

CardiologyNICEUpdated

Hypertension 2023

Updated NICE guidance on hypertension management for adults. Recommends ambulatory or home blood pressure monitoring for diagnosis, stepped-care treatment approach starting with ACE inhibitor or ARB, and defines new targets for different risk groups including CKD and diabetes subpopulations.

HypertensionBlood pressureACE inhibitor+3

64p2023UK

Respiratory MedicineERSNew

Severe COPD 2023

Joint ERS/ATS guidance on severe and very severe COPD (GOLD III–IV). Includes recommendations on long-term oxygen therapy thresholds, non-invasive ventilation at home, lung volume reduction interventions, and palliative care integration. Triple inhaled therapy (LABA/LAMA/ICS) preferred for frequent exacerbators.

COPDGOLD III-IVNIV+3

72p2023EU

RheumatologyEULARUpdated

Rheumatoid Arthritis 2022

Updated EULAR RA recommendations reinforce treat-to-target with DAS28 remission as primary goal. JAK inhibitors now carry updated cardiovascular and malignancy safety considerations. csDMARD monotherapy (MTX) remains first-line; biologics and JAKi added when targets not met after 3–6 months.

Rheumatoid ArthritisMTXbDMARD+3

58p2022EU

NephrologyKDIGONew

Chronic Kidney Disease 2024

Comprehensive update to KDIGO CKD guidelines. SGLT2 inhibitors now Class I for CKD with or without diabetes to slow progression. Finerenone recommended in diabetic CKD. Updated GFR equations (2021 CKD-EPI without race coefficient) and revised staging criteria for cardiorenal syndrome.

CKDSGLT2iFinerenone+3

94p2024INT

NeurologyAHA

Stroke Prevention 2021

Focused update on secondary stroke prevention. Dual antiplatelet therapy (aspirin + clopidogrel or ticagrelor) for 21 days following minor stroke/high-risk TIA is Class I. Intracranial stenting not recommended for symptomatic patients on maximal medical therapy.

StrokeTIASecondary prevention+3

82p2021USA

PsychiatryNICEUpdated

Depression 2022

Significant revision to NICE depression guidance. Stepped-care model restructured around severity and patient preference. Psychological therapies (CBT, behavioural activation) recommended first-line for mild-to-moderate depression. SSRIs remain recommended pharmacotherapy. New evidence on digital therapeutics and exercise integrated.

DepressionMDDSSRI+3

68p2022UK

CardiologyESC

Dyslipidaemia 2019

Defines aggressive LDL-C targets for high and very high CV risk: <1.4 mmol/L (<55 mg/dL) for very high risk with ≥50% reduction. PCSK9 inhibitors recommended for patients not at target on maximum tolerated statin + ezetimibe. Updated risk calculator SCORE2 for European populations.

DyslipidaemiaLDL cholesterolStatins+3

78p2019EU

Infectious DiseaseIDSA

Sepsis Management 2021

Updated Surviving Sepsis Campaign guidelines recommend 1-hour sepsis bundle initiation. Balanced crystalloids preferred over normal saline for resuscitation. Procalcitonin-guided antibiotic de-escalation recommended. Hydrocortisone for septic shock refractory to vasopressors. Early enteral nutrition within 24–48 hours.

SepsisSeptic shockAntibiotics+3

96p2021USA

CardiologyESC

Arterial Hypertension 2018

Defines hypertension as BP ≥140/90 mmHg and recommends single-pill combination therapy as initial treatment for most patients. Introduces the concept of out-of-office BP monitoring as preferred diagnostic method. Renal denervation evidence rated as insufficient for routine recommendation.

HypertensionBP targetsCombination therapy+3

98p2018EU

Respiratory MedicineNICEUpdated

Asthma Management 2021

Updated NICE asthma guidance endorses FeNO testing in the diagnostic pathway and recommends MART (Maintenance and Reliever Therapy) with ICS-formoterol as preferred treatment for adults with uncontrolled asthma on low-dose ICS. Removes SABA-only prescribing from first-line.

AsthmaICSMART therapy+3

52p2021UK

EndocrinologyEASDUpdated

T2DM Hyperglycaemia 2022

Joint ADA/EASD consensus prioritises cardiovascular risk, heart failure, and CKD as drivers of drug choice over glycaemic control alone. GLP-1 RAs and SGLT2-i move to second-line regardless of HbA1c when CV disease, HF or CKD is present. Personalised HbA1c targets 6.5–8.0% based on patient profile.

Type 2 DiabetesGLP-1 RASGLT2i+3

44p2022EU

CardiologyESC

Chronic Coronary Syndromes 2019

Replaces stable angina terminology with chronic coronary syndromes. Introduces functional testing and coronary CT angiography as first-line imaging. Anti-anginal therapy algorithm updated with ranolazine and ivabradine as add-on options. Aspirin 75–100 mg and statin remain Class I for all CCS.

Chronic Coronary SyndromesStable anginaCCTA+2

88p2019EU

CardiologyESCUpdated

Valvular Heart Disease 2021

Updated recommendations expand TAVI (TAVR) indications to lower-risk patients, with Heart Team decision mandatory. Transcatheter edge-to-edge repair (TEER) recommended for secondary MR in symptomatic patients with HFrEF. Anticoagulation strategy post-TAVI updated with VKA or NOAC depending on indication.

Valvular Heart DiseaseTAVIAortic stenosis+3

96p2021EU

Respiratory MedicineBTS

Bronchiectasis 2019

Comprehensive guidance on the investigation and management of non-CF bronchiectasis. Includes recommendations on long-term macrolide therapy for frequent exacerbators (≥3/year), airway clearance techniques, and microbiological surveillance. CT chest is the gold-standard diagnostic test.

BronchiectasisMacrolide therapyAirway clearance+2

48p2019UK

NephrologyKDIGONew

Acute Kidney Injury 2023

First major update to KDIGO AKI guidelines since 2012. Defines AKI staging, prevention strategies including IV fluid type, and updated dialysis initiation criteria. Remote ischaemic preconditioning added for high-risk surgical patients. Novel biomarkers (NGAL, KIM-1) discussed but not yet Class I.

AKIAcute kidney injuryDialysis+3

66p2023INT

CardiologyESCNew

Cardiac Pacing 2023

Focused update introducing conduction system pacing (His bundle pacing, left bundle branch pacing) as a Class IIa recommendation for CRT-eligible patients when conventional CRT is challenging. Leadless pacemakers receive Class I for single-chamber VVI pacing. Subcutaneous ICD indication refined.

Cardiac PacingCRTHis bundle pacing+3

42p2023EU

Full Access

Read every guideline in full.Start free, no card needed.

Unlock full guideline access, AI-powered summaries, CPD tracking, and comparison tools — free for the first 10 queries per day.

Create Free Account View Pricing